Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programsCompanies: NovartisIncludes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 2026 -- Abogen Biosciences ("Abogen" or...
- Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)Companies: NovartisNovartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx® (secukinumab) in polymyalgia rheumatica (PMR).⁸ The opinion supports Cosentyx use for treatment of PMR in adults who have had an inadequate response to steroids or who experience relapse during steroid taper.⁸ If approved, Cosentyx would be the first interleukin-17A (IL-17A) inhibitor approved in Europe for people living with PMR, a disease with very limited advanced treatment options.¹˒³⁻⁷
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenCompanies: NovartisRoyalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.
- Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)Companies: NovartisAd hoc announcement pursuant to Art. 53 LR
- Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution ChannelCompanies: AbbVieAmgenJohnson & JohnsonNovartisThe global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials, regulatory approvals and pharmaceutical R&D, despite high treatment costs and limited access in developing regions.
- Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapiesCompanies: NovartisNovartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. “The data we are presenting at this year’s ESC Congress underscore our commitment to advancing cardiovascular science for patients who remain at risk despite current treatment,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. “From foundational medicines Leqvio and Entresto to promising investigational therapies, our portfolio reflects our focus on addressing persistent challenges in cardiovascular care.” Key abstracts accepted by ESC include: